Noyada (captopril)
Numéro de dossier de l’AMC:
23268
État des négociations:
Négociation conclue par une lettre d’intention
Indication(s):
• for the treatment of essential or renovascular hypertension
• for the treatment of congestive heart failure
• to improve survival, delay the onset of symptomatic heart failure and reduce hospitalizations for heart failure following myocardial infarction in clinically stable patients with left ventricular dysfunction manifested as an ejection fraction of ≤ 40%.
• for the treatment of diabetic nephropathy (proteinuria ≥ 500 mg/day) in patients with type I insulin-dependent diabetes mellitus and retinopathy.
• for the treatment of congestive heart failure
• to improve survival, delay the onset of symptomatic heart failure and reduce hospitalizations for heart failure following myocardial infarction in clinically stable patients with left ventricular dysfunction manifested as an ejection fraction of ≤ 40%.
• for the treatment of diabetic nephropathy (proteinuria ≥ 500 mg/day) in patients with type I insulin-dependent diabetes mellitus and retinopathy.
Promoteur/fabricant:
Ethypharm Inc.
Numéro de projet de l’AMC:
Sans objet
Lettre d’entente de l’APP:
Conclusion du processus de négociation: